JPRN-jRCT2031210626招募中2 期
Satralizumab, an Anti-IL-6 receptor antibody, in the treatment of pulmonary arterial hypertension; safety and efficacy evaluation in Japan - Multicenter, Investigator-sponsored Trial- - SATISFY-JP Trial
Tamura Yuichi0 个研究点目标入组 20 人开始时间: 2022年2月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 80age old（—）
- 性别
- All
入选标准
- •1) Patients whose age at the time of consent acquisition is between 20 and 80 years old.
- •2) Patients who have been diagnosed with pulmonary arterial hypertension (PAH) and fall into one of the following among the first group of the clinical classification of pulmonary hypertension (Nice Classification, 2018)
- •Idiopathic pulmonary arterial hypertension (IPAH)
- •Hereditary pulmonary arterial hypertension (HPAH)
- •Drug/toxin-induced pulmonary arterial hypertension
- •Pulmonary arterial hypertension associated with connective tissue disease
- •Pulmonary arterial hypertension associated with congenital heart disease (only after repair surgery)
- •3) Patients in the World Health Organization (WHO) Functional Classification (FC) I, II, or III.
- •4) Patients with immune responsive-phenotype
- •5) Patients with a 6-minute walking distance of 150 to 600 meters at screening.
- •6) Patients whose resting hemodynamic values within 30 days prior to enrollment meet all of the following
- •Mean pulmonary artery pressure (mPAP) is 25 mmHg or higher
- •PVR is higher than 4 Wood units
- •7) Patients who are using up to three PAH drugs and have not changed the dosage and administration for at least 90 days prior to enrollment
- •8) Patients who are receiving home oxygen therapy under the same conditions for at least 30 days prior to enrollment
- •9) Patients who have given written consent for the study
排除标准
- •1) Patients with a history of severe allergy to any of the components of the study drug.
- •2) Patients who have received IL-6 inhibitors (tocilizumab, sarilumab, etc.) in the past or are currently receiving them at the time of screening.
- •3) Patients with infectious diseases such as pneumonia or tuberculosis during the screening period.
- •4) Patients with pulmonary artery wedge pressure (PAWP) greater than 15 mmHg on the last right heart catheterization performed during the screening period.
- •5) Patients who are using epoprostenol (intravenous) or treprostinil (intravenous or subcutaneous) and cannot discontinue.
- •6) Patients who are currently participating in other clinical trials or clinical studies. Or, patients who have participated in other clinical trials/trials prior to participation in this study and whose adverse events, if any, have occurred during the period of participation and have not been confirmed to have resolved or stabilized
- •7) Pregnant women or lactating patients.
- •8) Patients who are unable to consent to contraception from the time of obtaining consent until at least 3 months after the last dose of the study drug
- •9) Patients who have received a live vaccine within 6 weeks prior to enrollment
- •10)Patients who are positive for HIV-1 antibody, HIV-2 antibody, HTLV-1 antibody, HBs antigen, or HCV antibody.
- •11)Patients with active or recurrent bacterial, viral, fungal, or mycobacterial infections, or with other infectious diseases
- •12) Patients who have been hospitalized or developed an infection requiring intravenous administration of an infectious agent within 4 weeks prior to the baseline visit or an infection requiring oral administration of an infectious agent within 2 weeks prior to the baseline visit.
- •13) Patients who are receiving steroids at a dose higher than 10 mg/day of prednisone (PSL) equivalent.
- •14)Patients with a history of malignancy, including solid tumors, hematologic malignancies, and intraepithelial carcinomas, within the past 5 years.
- •15) Patients who are judged to lack the capacity to consent.
- •16) Other patients who are judged by the investigator to be unsuitable for the study.
研究者
相似试验
撤回
早期 1 期
Study on the Use of Sarilumab in Patients With COVID-19 InfectionCOVID19NCT04386239ASST Fatebenefratelli Sacco
进行中（未招募）
1 期
sing the medicine 'interleukin-6 receptor antagonists' to inhibit the inflammation in patients resuscitated from cardiac arrest.We investigate the efficacy of commercially available interleukin-6 receptor antibody 'RoActemra' for reducing the systemic inflammatory response in patients having been resuscitated after out-of-hospital cardiac arrest. This study is a double-blind, randomized pilot trial.MedDRA version: 20.0Level: PTClassification code 10007515Term: Cardiac arrestSystem Organ Class: 10007541 - Cardiac disordersEUCTR2018-002686-19-DKDepartment of Cardiology, Copenhagen University Hospital Rigshospitalet80
进行中（未招募）
不适用
Evaluation effects of treatment with an inhibitor of the receptor of a protein (interleukin-6 IL-6)involved in inflammatory process, on the clinical response and on the changes from baseline in the biomarkers in patients with rheumatoid arthritis (RA)not responding adequately to Disease-modifying antirheumatic drugs (DMARDs) and/or to a first biological agent.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-001760-30-ITOSSERVATORIO EPIDEMIOLOGICO GISEA
招募中
2 期
se of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD)ACTRN12614000212651Royal Brisbane and Women's Hospital18
撤回
3 期
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia RheumaticaPolymyalgia RheumaticaNCT02899026GlaxoSmithKline